CorpDev.Org
Daily News for Dealmakers
Big Deal
Trump 2025: Deregulation Fuels Breakout Mergers & Acquisitions
Deregulation Catalyst: A potential Trump presidency in 2025 could significantly boost M&A activity, driven by anticipated deregulation initiatives and a more business-friendly regulatory environment. Historical Precedents: Past periods of...
Trump’s 2025 Return May Spark M&A Boom with Deregulation Agenda
Deregulation Catalyst: A potential second Trump presidency in 2025 could usher in a new era of deregulation, stimulating a fresh wave of M&A activity across various sectors. Historical Precedent: The 2003-2007 M&A boom was largely driven by...
Comcast considers cable spinoff
Strategic Shift: Comcast explores spinning off cable channels to focus on streaming service Peacock, adapting to changing media consumption trends. Market Opportunity: Global streaming market projected to reach $243 billion by 2025, driven by...
Siemens Acquires Altair for $10.6 Billion: A Strategic Tech Move
Strategic Acquisition: Siemens signs definitive agreement to acquire Altair for $10.6 billion, bolstering its digital portfolio with cutting-edge software solutions. Transaction Details: Altair stockholders to receive $113 per share in cash,...
AMD’s Aggressive M&A Strategy Challenges Nvidia’s AI Dominance
Strategic Acquisitions: AMD's $4.9 billion acquisition of ZT Systems, a leading AI and cloud computing systems provider, positions it as a formidable challenger to Nvidia in the rapidly growing AI infrastructure market. Enhancing AI Capabilities:...
Top Jobs Currently Hiring
Private Equity
International
Tech, Media & Telecom
Financial Services
Health & Life Sciences
Boston Scientific Boosts AF Treatment with Cortex Acquisition
Strategic Acquisition: Boston Scientific's acquisition of Cortex, Inc. expands its electrophysiology portfolio with the OptiMap System, a diagnostic mapping solution for complex atrial fibrillation (AF) cases. Unmet Need: The OptiMap System...
Relief Therapeutics Boosts Pipeline with Renexxion’s Reverse Merger
Strategic Reverse Merger: Relief Therapeutics, a Swiss biotech firm, signs non-binding letter of intent for a reverse merger with Renexxion, a U.S. clinical-stage biotech company focused on gastrointestinal therapies. Expanded Pipeline: The merger...
Biotech Merger: Relief & Renexxion Aim to Revolutionize Gastrointestinal Therapies
Strategic Rationale: The merger aims to leverage Relief's expertise in rare diseases and Renexxion's gastrointestinal therapies, bolstering their competitive stance and accelerating novel treatment development. Valuation and Ownership: The deal...
AbbVie’s $1.4B Alzheimer’s Bet: Game Changer or Risky Gamble?
Strategic Acquisition: AbbVie's $1.4 billion acquisition of Aliada Therapeutics signals a significant bet on Alzheimer's disease treatment, bolstering its pipeline with a Phase I anti-amyloid antibody, ALIA-1758. Blood-Brain Barrier Technology: The...
Roche vs. Novo-Catalent Deal: Shaping Pharma’s Competitive Future
Competitive Landscape: Roche CEO Thomas Schinecker urges regulators to block Novo Holdings' $16.5B acquisition of Catalent, citing concerns over reduced competition and potential negative impacts on innovation, drug availability, and pricing in the...
